Utility of 18F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer

被引:0
作者
Ravina, Mudalsha [1 ,2 ]
Saboury, Babak [3 ]
Chauhan, M. S. [1 ]
Jacob, M. J. [1 ]
Pandit, A. G. [1 ]
Sanchety, Naveen [4 ]
Werner, Thomas J. [3 ]
Alavi, Jane [3 ]
Alavi, Abass [3 ]
机构
[1] Army Hosp Res & Referral, Dept Nucl Med, New Delhi, India
[2] All India Inst Med Sci, Raipur, Madhya Pradesh, India
[3] Hosp Univ Penn, Dept Radiol, Div Nucl Med, Philadelphia, PA 19104 USA
[4] Army Hosp Res & Referral, Dept Surg Oncol, New Delhi, India
来源
HELLENIC JOURNAL OF NUCLEAR MEDICINE | 2019年 / 22卷 / 03期
关键词
Breast Cancer; F-18-FDG-PET/CT; Prognosis of BC; Staging of BC; POSITRON-EMISSION-TOMOGRAPHY; HORMONE-RECEPTOR STATUS; STAGE-I; FDG-PET; PATHOLOGICAL FEATURES; ESTROGEN-RECEPTORS; PROGNOSTIC-FACTORS; FOLLOW-UP; CARCINOMA; ASSOCIATION;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: To determine the correlation between fluorine-18-fluorodeoxyglucose (F-18-FDG)uptake values and clinicopathological prognostic markers using preoperative F-18-FDG positron emission tomography/computed tomography (PET/CT) in primary breast cancer (BC). Subjects and Methods: One hunrded and twelve patients with primary BC were studied prospectively. Pretreatment F-18-FDG PET/CT was performed. Maximum standardized uptake values (SUVmax) were compared with various clinicopathological variables. Results: In a univariate analysis, SUVmax correlated well with the following prognostic variables: T stage, absence of progesterone receptor (PR), absence of estrogen receptor (ER), triple negative lesions (ER/PR and Her 2 negative) and high histologic grade. Metastatic lesions and ductal lesions had higher SUVmax than lobular carcinoma. No significant correlation was found between SUVmax, and human epidermal growth factor receptor 2 (Her-2) status or perineural and lymphovascular invasion. Multivariate analyses showed that breast density, tumor size and PR negativity were significantly correlated with SUVmax (P=0.046 and 0.009, respectively). Conclusion:The pre-treatment tumor SUVmax could be utilized as an independent imaging biomarker of the tumor aggressiveness and poor prognosis. Risk stratification based on this index could play a pivotal role in alteration of treatment planning, such as neoadjuvant chemotherapy (precision oncology).
引用
收藏
页码:165 / 171
页数:7
相关论文
共 44 条
  • [1] Albain K S, 1994, J Natl Cancer Inst Monogr, P35
  • [2] [Anonymous], 2007, CANC FACTS FIG 2007
  • [3] Avril N, 2001, J NUCL MED, V42, P9
  • [4] Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters
    Basu, Sandip
    Chen, Wengen
    Tchou, Julia
    Mavi, Ayse
    Cermik, Tevfik
    Czerniecki, Brian
    Schnall, Mitchell
    Alavi, Abass
    [J]. CANCER, 2008, 112 (05) : 995 - 1000
  • [5] FDG uptake in breast cancer:: correlation with biological and clinical prognostic parameters
    Buck, A
    Schirrmeister, H
    Kühn, T
    Shen, CX
    Kalker, T
    Kotzerke, J
    Dankerl, A
    Glatting, G
    Reske, S
    Mattfeldt, T
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2002, 29 (10) : 1317 - 1323
  • [6] Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer:: a preliminary observation
    Crippa, F
    Seregni, E
    Agresti, R
    Chiesa, C
    Pascali, C
    Bogni, A
    Decise, D
    De Sanctis, V
    Greco, M
    Daidone, MG
    Bombardieri, E
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (10) : 1429 - 1434
  • [7] Dawson S J, 2009, Eur J Cancer, V45 Suppl 1, P27, DOI 10.1016/S0959-8049(09)70013-9
  • [8] DEHDASHTI F, 1995, J NUCL MED, V36, P1766
  • [9] Re: Tumor characteristics and clinical outcome of elderly women with breast cancer - Response
    Diab, SG
    Elledge, RM
    Clark, GM
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (01) : 65 - 66
  • [10] Favier L, 2007, J CLIN ONCOL, P505